Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: A medical device company focused on bone regeneration in spinal fusion using the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The company is in the development stage with no commercial revenue to date. It holds an exclusive license from UCLA TDG for its technology.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(941,002) | $(2,590,705) | $(7,398,846) |
| Net Loss Attributable to Common Stockholders | $(4,153,506) | $(5,803,209) | $(7,398,846) |
| Operating Expenses | $951,021 | $2,664,223 | $8,268,295 |
| Cash and Cash Equivalents (End of Period) | $3,566,426 | $3,566,426 | $4,452,586 |
| Net Cash Used in Operating Activities | N/A | $(2,771,438) | $(7,537,889) |
| Net Cash Provided by Financing Activities | N/A | $3,311,295 | $4,452,163 |
| Accumulated Deficit | $(83,499,663) | $(83,499,663) | $(79,359,073) |
Note: The significant increase in Net Loss Attributable to Common Stockholders for Q3 and YTD 2024 includes a non-cash "deemed dividend" of $3,212,504 related to a warrant inducement.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased significantly by 67.8% year-over-year for the nine months ended September 30, 2024 ($2.66M vs. $8.27M). This reduction is primarily due to lower Research and Development (R&D) costs ($1.03M vs. $6.46M), attributed to the completion of significant protein production expenses in 2023 required for the initial clinical study.
- Warrant Liability: The change in fair value of warrant liability shifted from a gain of $867,930 in the prior year period to a gain of $38,122 in the current period, reflecting re-measurement of outstanding liabilities.
- Capital Structure: The company completed a public offering in March 2024 and a warrant inducement exercise in August 2024, resulting in significant share issuance and cash inflows. Common shares outstanding increased from 534,238 at year-end 2023 to 2,096,740 as of September 30, 2024.
- Liquidity: Cash balances increased from $3.03M at December 31, 2023, to $3.57M at September 30, 2024, driven by financing activities offsetting operating cash burn.
Outlook, Risks, and Unusual Items
- Going Concern: The company has incurred accumulated losses of approximately $83.5 million since inception. Management estimates operating expenditures for the next twelve months at $5.4 million. Current cash is anticipated to cover operational needs into the second quarter of 2025. The filing states these factors raise substantial doubt about the company's ability to continue as a going concern.
- Clinical Progress: On June 20, 2024, the first patient was treated in a multicenter, prospective, randomized pilot clinical study of the NB1 bone graft device in Australia. This triggered a $100,000 milestone payment to UCLA TDG.
- Unusual Items: A non-cash deemed dividend of $3,212,504 was recorded in Q3 2024 resulting from an August 2024 warrant inducement where existing warrants were exercised for cash in exchange for new warrants with more favorable terms.
- Future Financing: The company entered into an "At The Market" (ATM) offering agreement in September 2024 to sell up to approximately $1.1 million of common stock. Subsequent to the period end, $640,613 in net proceeds were raised through this facility.
- Risks: Key risks include the inability to raise additional capital, failure to obtain FDA approval for NELL-1/DBM, and reliance on third-party manufacturers. The company is also subject to significant royalty and milestone obligations under its license with UCLA TDG.
Investor Verification Checklist
- Cash Runway: Verify if the $3.6M cash balance is sufficient to fund the estimated $5.4M in operating expenditures for the next 12 months without further dilution.
- Dilution Impact: Assess the impact of the recent warrant inducement and ATM offering on existing shareholders, noting the issuance of 1.56M new inducement warrants and the potential for further share sales.
- Clinical Milestones: Monitor the progress of the NB1 pilot clinical study in Australia and the timeline for the subsequent pivotal study required for FDA approval.
- License Obligations: Review the specific diligence milestones and royalty payments owed to UCLA TDG, including the $8M "Diligence Fee" payable upon commercial sales.
- Going Concern Status: Evaluate the company's specific plans for raising the additional capital required to bridge the gap between current cash reserves and the estimated $29M total needed for FDA approval.